Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. Also provided are vaccine formulations comprising mammalian or avian MPV, including recombinant and chimeric forms thereof. The vaccine preparations encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.

The present invention relates to a gas-generating micelle prepared by coupling a polyethylene glycol derivative and an alkyl chloroformate. The gas-generating micelles according to the present invention are circulated in the body and deposited on the disease site to generate carbon dioxide, and thus a more enhanced ultrasonic diagnostic image can be obtained.

The present disclosure relates to a method for labeling a radioisotope includes providing a cyclooctyne compound represented by the following formula (I), and to which a biomolecule, a fluorescent dye, or a nanoparticle compound is bound, and reacting the cyclooctyne compound with a quinone compound represented by the following formula (II) and labeled with the radioisotope in room temperature; a radiolabeling compound represented by the following formula (II), for labeling a molecule having a cyclooctyne moiety; and a composition for medical diagnosis or for treating cancer comprising a quinone compound represented by the following formula (II) and labeled with the radioisotope:

##STR00001##

in formula (I), Z is the biomolecule, the fluorescent dye, or the nanoparticle compound,

##STR00002##

in formula (II), b is 0 or an integer from 1 to 10; L is CH.sub.2, COO, or CONH; M is the radioisotope.

The present disclosure provides peptides useful as inhibitors of the dimerization interface of EBNA1. The present disclosure also provides methods for treating and imaging EBV-associated cancers.

An infusion system may include a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to determine an activity of rubidium in the radioactive eluate based on the beta emissions measured by the beta detector and determine an activity of strontium in the radioactive eluate based on the gamma emissions measured by the gamma detector.

Provided is a novel nanoparticle, a contrast agent for magnetic resonance imaging containing the same, and a ligand compound used for production of the nanoparticle. The present invention relates to a nanoparticle including: a metal particle containing iron oxide; and a ligand which is bound to a metal atom on a surface of the metal particle and is represented by formula (3):

##STR00001##

where m is an integer of 1 to 4, and a broken line represents a coordinate bond with a metal atom on the surface of the metal particle.

Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen, pharmaceutical composition comprising the same and methods of use thereof are disclosed.

The present invention relates to novel peptides derived from Actin-like protein 8 (ACTL8), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

The present invention relates to compounds which bind and/or inhibit prostate-specific membrane antigen (PSMA) comprising at least one group electron dense substituent (EDS), and at least one moiety which is amenable to radiolabeling; and therapeutic and diagnostic uses thereof.

The present application provides compounds useful in methods of treating neurological disorders such as Alzheimer's disease, and cancer such as prostate cancer. Also provided herein are radiolabeled compounds useful for imaging techniques, and techniques for diagnosis and monitoring of treatment of neurological disorders and cancer. An exemplary radiolabeled compound provided herein is useful as a radiotracer for positron emission tomography or single-photon emission computed tomography. Methods for preparing radiolabeled compounds and methods for preparing unlabeled compounds are also provided.